On November 24, Shanghai Jiangeng Pharmaceutical Technology Co.
, Ltd.
submitted a prospectus (declaration draft)
for its initial public offering and listing on the Science and Technology Innovation Board.
The number of shares issued in this public offering shall not exceed 23,467,200 shares (including 23,467,200 shares, and not less than 25% of the total share capital of the company after this offering).
It is understood that this is not the first time that Jiangeng Pharma has broken through the IPO, after its IPO on the Science and Technology Innovation Board withdrew its listing application on the eve of the meeting, and the IPO of the Science and Technology Innovation Board was terminated
.
This time, after the IPO of Shanghai Jiangeng Pharmaceutical's second breakthrough on the science and technology innovation board is accepted, it is expected to raise 1.
023 billion yuan, and the funds raised will be used for organ transplantation innovation and R&D platform projects, kidney transplantation equipment localization and upgrading R&D projects, liver transplantation equipment and in vitro diagnostic reagent product registration and promotion projects in the field of transplantation, information system construction projects and supplementary working capital
.
Looking back at the first three quarters, in fact, the enthusiasm of pharmaceutical companies to file IPOs has been very high
.
Since the second half of the year, the number of IPO filings by enterprises has surged
.
For example, on November 8, Lepu Xintai Medical Technology (Shanghai) Co.
, Ltd.
was listed
on the Hong Kong Stock Exchange.
The number of shares issued in this offering was 22.
455 million shares at an issue price of HK$29.
15 per share, raising a net amount of approximately HK$
552 million.
It is reported that about 50.
7% of its net proceeds will be used to fund R&D activities over the next five years; Approximately 24.
3% will be used for sales and marketing activities in the next five years; Approximately 5.
0% will be used to increase production capacity and strengthen manufacturing capacity in the next five years; Approximately 10.
0% will be used to fund potential strategic investments and acquisitions over the next five years to complement and expand the Company's product portfolio and technology; Approximately 10.
0% will be used for working capital and general corporate purposes
.
On October 19, Shandong Baiduoan Medical Equipment Co.
, Ltd.
disclosed the prospectus (declaration draft) that the number of shares that the company intends to publicly issue this time shall not exceed 20.
52 million shares, accounting for no less than 25% of the total share capital after issuance, subject to the number after the registration is approved by the China Securities Regulatory Commission
.
In this IPO of the Science and Technology Innovation Board, Baiduoan plans to raise 760 million yuan for the industrialization and upgrading project of medical catheters, the construction project of R&D center, the construction project of marketing service network and information technology, and the supplementary working capital project
.
On October 18, Henrun Dasheng submitted an IPO application on the Science and Technology Innovation Board, and the prospectus was officially made public
.
Henrun Dasheng plans to raise RMB 2,539.
48 million in this IPO of the Science and Technology Innovation Board, of which RMB 1.
337 billion will be used for cell therapy research and development, RMB 600 million will be used for the construction of headquarters and industrialization bases, and RMB 600 million will be used to supplement working capital
.
On October 13, the GEM Listing Committee of the Shenzhen Stock Exchange held the 73rd Listing Committee Deliberation Meeting in 2022, and two companies, Wanbang Pharmaceutical and Kaishi Biologics, will be reviewed
for IPOs on the Growth Enterprise Market.
Among them, Wanbang Pharmaceutical plans to raise 484 million yuan, 404 million yuan for the drug research and development and pharmacokinetic engineering center project, including clinical trial service capacity improvement project, pharmaceutical research center upgrading construction project and innovative drug development platform construction project, 80 million yuan for working capital replenishment project
.
Kaishi Biologics intends to raise 700 million yuan, which will be used for in vitro diagnostic product production base projects, in vitro diagnostic instrument research and development projects and supplementary working capital
.
.
.
.
.
.
.
Statistics show that since the beginning of 2022, 270 companies have implemented fixed increases, with a total amount of 532.
123 billion yuan
.
Among them, in the pharmaceutical industry, there are also 3 pharmaceutical companies that have even raised more than 3.
5 billion yuan, namely Shanghai Pharmaceutical, Fosun Pharma and Aier Ophthalmology
.
The industry believes that on the whole, most domestic pharmaceutical companies are undoubtedly raising funds to increase the layout of innovative research and development and focus on the main business
.
In the future, with the continuous investment of related enterprises, it is expected that more innovative drugs and innovative medical devices are expected to accelerate.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
